CMAB807 (denosumab biosimilar) / 3SBio - LARVOL DELTA

Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® . (clinicaltrials.gov) - P3 | N=278 | Completed | Sponsor: Shanghai Biomabs Pharmaceutical Co., Ltd. | Recruiting ➔ Completed

Trial completion • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy Volunteers (clinicaltrials.gov) - P1 | N=128 | Completed | Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd | Recruiting ➔ Completed

Trial completion

Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy Volunteers (clinicaltrials.gov) - P1 | N=132 | Recruiting | Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd

New P1 trial

Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® . (clinicaltrials.gov) - P3 | N=278 | Recruiting | Sponsor: Shanghai Biomabs Pharmaceutical Co., Ltd. | Trial completion date: Nov 2023 ➔ Nov 2024 | Trial primary completion date: Oct 2023 ➔ Oct 2024

Trial completion date • Trial primary completion date • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® . (clinicaltrials.gov) - P3 | N=278 | Recruiting | Sponsor: Shanghai Biomabs Pharmaceutical Co., Ltd. | Trial completion date: Jun 2023 ➔ Nov 2023 | Trial primary completion date: Jan 2023 ➔ Oct 2023

Trial completion date • Trial primary completion date • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects. (PubMed, Front Pharmacol) - P1 | "NCT03925051), http://www.chinadrugtrial/org.cn/index.html (Registration No. CTR20190800)."

Clinical • Journal • PK/PD data • Osteoporosis • Rheumatology

Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® . (clinicaltrials.gov) - P3; N=278; Recruiting; Sponsor: Shanghai Biomabs Pharmaceutical Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Maintaining Bone Density When Discontinuing Denosumab (myCME) - "Released: January 20, 2021; Expires: January 20, 2022; At the conclusion of this activity, participants should be better able to: Describe the effects of denosumab treatment in patients with osteoporosis, including the mechanisms by which it achieves these effects, Outline clinical data related to mitigating adverse events following discontinuation of denosumab."

Online CME

Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® . (clinicaltrials.gov) - P3; N=278; Not yet recruiting; Sponsor: Shanghai Biomabs Pharmaceutical Co., Ltd.

Clinical • New P3 trial • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology